Govt's ammonia rule to hurt pharma cos as directive restricts sale of surplus to fertiliser firmsIndia’s pharmaceutical industry faces a potential raw material crunch after the government restricted surplus ammonia supply to fertiliser ...
Crude cargo traffic likely to get caught up in war logjam againA US naval blockade of Iranian ports, following failed ceasefire talks, has increased uncertainty over energy cargo movements and the risk ...
Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
Tariff therapy: Trump nudges pharma cos to make drugs in US or face 100% tariffAmerica is set to impose hefty 100% tariffs on imported medicines. This move targets drug companies that do not agree to government pricing...
Cipla to tap foreign cos for large-scale vax playMoving beyond a wide portfolio of Covid drugs and diagnostic kits, the Mumbai-based company — with revenues of nearly Rs 20,000 crore — now...
Indian govt's schizophrenia led to COVID ravages: Amartya SenIndia was better placed to fight the pandemic because of its pharma manufacturing prowess and also higher immunity levels, the noted econom...
AstraZeneca further cuts EU vaccine supply target to 30 million: DocumentThe AstraZeneca document, shared with EU officials and dated March 10, shows that the company now expects to deliver 30.1 million doses by ...
Seven Nifty firms that are likely to log over 50% jump in Q3 profitMotilal Oswal Securities expects the combined sales of Nifty constituents for the September-December period to fall 2 per cent YoY.
Competition, delay in drug approvals may take a toll on pharma cos' healthWith global macro-economic scenario turning volatile, Indian players may have to strategise harder to stay ahead.
Pharma companies adopt tough ethical normsAfter facing flak for illegal drug trials, and unethical marketing practices, the pharma industry seems to be pulling up its socks.
- Elder Pharmaceuticals gets suitability certificate from EDQM for Diosmin
Drug firm Elder Pharmaceuticals today said it has received certificate of suitability for 'Diosmin API', a drug used for the treatment of d...
- Buy Dr Reddy’s on declines: Mitesh Thacker
Probably look to buy into if there are more corrections and if the stock price declines to 1400-1020 odd levels.
- 'Emerging biz in India on track for building leadership talent'
Though there is a shortfall of ‘leaders’ in India , new biz and pharma cos are gradually bridging the demand-supply gap, according to consu...
- Emami frontrunner to bag Paras Pharma for about Rs 3,000 cr
Emami, which has shown a keen interest in Paras Pharma ever since the beginning of the bidding game, is understood to be shelling out aroun...
- Aurobindo allots 1.6 lakh equity shares to FCCB holders
Drug maker Aurobindo Pharma today said it has allotted 1.66 lakh shares worth 20 million dollars (about Rs 94 crore) to some of the company...
- Pharma cos focus on specialist therapies
Pharma cos's emphasis is shifting to more focused therapies for specific cancers, immunological conditions and complex diseases.
- Blogs provide window to pharmaceutical industry in India
Discussions are posted by bloggers on ayurveda, biogenerics, combination drugs, patents, HIV as well as individual pharma cos. Scripting In...